F8 and autoimmune hemolytic anemia: Moreover, addition of excessive FVIII concentrates fails to neutralize the inhibitory activity of type II inhibitors in vitro, making management of AHA difficult in the clinical setting and high-dose replacement therapy with FVIII concentrates unsuccessful in AHA patients with high-titer inhibitors.